Jaguar Health Seeks Approval for Up to 92.9% Dilution, Reverse Split, and ELOC Floor Price Cut
JAGX sits 91% above its 52-week low of $2.35 on light trading volume (0.3× avg).
Summary
Jaguar Health's definitive proxy seeks approval for up to 92.9% dilution through CVP debt/preferred exchanges, a reverse split up to 1-for-150, and a cut in the ELOC floor price from $16.50 to $1.10.
Key Events · Financing and Capital Events · JAGX
-
CVP Exchange Could Deliver 92.9% Dilution
Proposal 1 authorizes issuance of up to 25,390,851 shares upon full exchange of Series Q Preferred Stock and CVP Debt at a $1.00 exchange price — representing 92.9% of the 1,945,542 shares outstanding as of September 25, 2026.
-
ELOC Floor Price Cut to $1.10
Proposal 5 reduces the ELOC floor price from $16.50 to $1.10 per share, enabling draws on the $40 million C/M Capital equity line at prices far below the current $4.50 stock price.
-
Reverse Split Up to 1-for-150
Proposal 4 grants the board discretion to effect a reverse stock split between 1-for-2 and 1-for-150 within one year, aimed at regaining Nasdaq compliance and facilitating strategic transactions.
-
Warrant Repricing to $1.00
Proposal 2 reprices investor warrants with exercise prices from $525 to $3,996.60 down to $1.00, and adds entitlement to 45,511 Series O and 20,260 Series R conversion shares upon exercise.
Analysis · JAGX · Life Sciences
The definitive proxy for the November 6 special meeting puts a package of highly dilutive financing measures before shareholders. Proposal 1 alone could hand CVP affiliates up to 25.4 million shares — 92.9% of the current outstanding count — if exchanges occur at a $1.00 price. Proposal 5 cuts the ELOC floor price from $16.50 to $1.10, unlocking the $40 million equity line at prices far below the current $4.50 stock price. Combined with a proposed reverse split of up to 1-for-150 and a 14% equity plan increase, this is a survival financing package for a company with only $3.8 million in cash and a going concern warning. The board is asking shareholders to approve massive dilution to keep the company funded.
How filings like this one have moved
In the 30 days to Oct 8, 2026, 43% of the 323 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.62%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAGX was trading at $4.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.8M. The 52-week trading range was $2.35 to $1,267.88. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.